The whole underlying theme here is this stigma and bias of not recognizing obesity as a disease like we do cancer and diabetes and everything else, says Florencia Halperin, an endocrinologist and chief medical officer at Form Health, an online medical weight loss clinic, For cancer, you would never have an employer who says, We're not covering this. Amanda Bonello, founder and CEO of the GLP-1 Collective, a nonprofit organization aiming to help patients access these medications, is not surprised at the lengths patients are going to
Wearable/disposable sweat-based glucose monitoring device with multistage transdermal drug delivery module
Based on comparable pharmaceutical mass tort litigation and the projected valuation of current claims, lower-value gastrointestinal injury cases may potentially resolve between approximately $50,000 and $150,000 depending on the severity of symptoms and medical treatment involved
Wrap-around care is critical, but payers are generally not in a place to align across benefits (and struggling with leadership to invest even more money, when GLP-1s are already heavily impacting budgets)